References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2024-3-85-91

mrj-1593

Research Article

ОБЗОРЫ

REVIEWS

Некоторые особенности остеогенеза при анкилозирующем спондилите и возможности лечения бисфосфонатами

Some features of osteogenesis in ankylosing spondylitis and the possibilities of treatment with bisphosphonates

https://orcid.org/0000-0003-3051-219X

Дацина

А. В.

Datsina

A. V.

Анастасия Валерьевна Дацина

115522; Каширское шоссе, 34А; Москва

Anastasia Valerievna Datsina

115522; 34A, Kashirskoe Shosse; Moscow

adasina@yandex.ru

https://orcid.org/0000-0003-3195-5187

Эрдес

Ш. Ф.

Erdes

S. F.

115522; Каширское шоссе, 34А; Москва

115522; 34A, Kashirskoe Shosse; Moscow

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2024

15062024

1838591

2024

Дацина А.В., Эрдес Ш.Ф.

Datsina A.V., Erdes S.F.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1593

Несмотря на высокую эффективность доступных в настоящее время таргетных синтетических базисных противовоспалительных препаратов (тсБПВП) и генно-инженерных биологических препаратов (ГИБП), примерно у 40 % пациентов с анкилозирующим спондилитом (АС) по данным клинического и лабораторно-инструментального исследования не удается достичь целей лечения. Кроме того, сопутствующие заболевания при АС, которые требуют интегрального подхода с участием разных специалистов, могут ограничивать применение такой терапии. Учитывая сказанное, а также особенности костного метаболизма при АС, в последнее время уделяется внимание поиску новых терапевтических подходов при этом заболевании, одним из которых является применение бисфосфонатов. В статье рассмотрены некоторые аспекты костного метаболизма и нестандартные терапевтические возможности – использование бисфосфонатов при АС, осложненном тяжелыми коморбидными состояниями, у пациентов с недостаточной эффективностью ГИБП и/или тсБПВП.

Despite the high efficacy of currently available targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and biologic DMARDs (bDMARDs), approximately 40 % of patients with ankylosing spondylitis (AS) fail to achieve treatment goals according to clinical, laboratory and imaging tests. In addition, comorbidities in AS, which require an integrated approach involving different specialists, may limit the use of such therapy. In view of the above, as well as the peculiarities of bone metabolism in AS, new therapeutic approaches for this disease have recently been sought, one of which is the use of bisphosphonates. This article discusses some aspects of bone metabolism and unconventional therapeutic options – the use of bisphosphonates in AS complicated by severe comorbidities, in patients with insufficient efficacy of bDMARDs and/or DMARDs.

спондилоартритбисфосфонатыбазисные противовоспалительные препаратыгенно-инженерные биологические препаратынеэффективность терапии

spondyloarthritisbisphosphonatesbasic anti-inflammatory drugsgenetically engineered biological productsineffectiveness of therapy

Статья подготовлена в рамках научной темы № 1021051503111-9. Исследование не имело спонсорской поддержки

The article was prepared within the framework of a research work № 1021051503111-9. The investigation has not been sponsored

References1

Клинические рекомендации. Анкилозирующий спондилит. https://library.mededtech.ru/rest/documents/cr_175/

Clinical recommendations. Ankylosing spondylitis. https://library.mededtech.ru/rest/documents/cr_175/

Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis.2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.

Эрдес ШФ, Сахарова КВ, Дубинина ТВ, Черкасова МВ. Клинические особенности больных анкилозирующим спондилитом с неэффективностью двух и более генно-инженерных биологических препаратов. Современная ревматология. 2023;17(3): 30-36. doi:10.14412/1996-7012-2023-3-30-36.

Erdes ShF, Sakharova KV, Dubinina TV, Cherkasova MV. Clinical features of patients with ankylosing spondylitis with inefficacy of two or more biological disease modifying antirheumatic drugs. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2023;17(3): 30-36. (In Russ.). doi: 10.14412/1996-7012-2023-3-30-36.

Lopez-Medina С, Molto А. Comorbidity management in spondyloarthritis. MD Open. 2020 Sep;6(2):e001135. doi: 10.1136/rmdopen-2019-001135.

Papagoras С, Voulgari РV, Drosos АА. Cardiovascular disease in spondyloarthritides. Curr Vasc Pharmacol. 2020;18(5):473-487. doi: 10.2174/1570161117666190426164306.

Tsur АМ, David P, Watad A, et al. Ankylosing spondylitis and the risk of hip fractures: a matched cohort study. J GEN INTERN MED. 2022 Oct;37: 3283–88. doi: 10.1007/s11606-021-07241-2. Epub 2022 Apr 11.

Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2011 Apr;63(4):550-6. doi: 10.1002/acr.20408.

Molto A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOСРА study. Ann Rheum Dis. 2016 Jun;75(6):1016-23. doi: 10.1136/annrheumdis-2015-208174. Epub 2015 Oct 21.

Casals-Sanchez JL, Garcia De Yebenes-Prous MJ, Descalzo Gallego MA, et al. Characteristics of patients with spondyloarthritis followed in rheumatology units in Spain. emAR II study. Reumatol Clin. 2012 May-Jun;8(3):107-13. doi: 10.1016/j.reuma.2012.01.006. Epub 2012 Apr 1.

Clunie G, Horwood N. Loss and Gain of Bone in Spondyloarthritis: What Drives These Opposing Clinical Features? Ther Adv Musculoskelet Dis. 2020 Oct 30:12:1759720X20969260. doi: 10.1177/1759720X20969260. eCollection 2020.

Ghozlani I, Ghazi M, Nouijai A, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009 May;44(5): 772-6. doi: 10.1016/j.bone.2008.12.028. Epub 2009 Jan 14.

Губарь ЕЕ, Эрдес ШФ. Остеопороз у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2013;51(5):553-62. doi: 10.1146/annurev-immunol-032414-112110.

Gubar' EE, Erdes ShF. Osteoporosis in patients with ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya. 2013;51(5): 553-62. (In Russ.).

Bowness P. HLA-B27. Annu Rev Immunol. 2015:33:29-48. doi: 10.1146/annurev-immunol-032414-112110.

Kavadichanda CG, Geng J, Bulusu SN, et al. Spondyloarthritis and the Human Leukocyte Antigen (HLA)-B*27 Connection. Front. Immunol. 2021 Mar;8:12:601518. doi: 10.3389/fimmu.2021.601518.

Layh-Schmitt G, Yang EY, Kwon G, Colbert RA. HLA-B27 Alters the response to tumor necrosis factor and promotes osteoclastogenesis in bone marrow monocytes from HLA-B27-transgenic rats: cellular effects of HLA-B27 misfolding in transgenic rats. Arthritis Rheum. 2013 Aug;65(8):2123-31. doi: 10.1002/art.38001.

Papet I, Yousfi ME, Godin J-P, et al. HLA-B27 Rats Develop Osteopaenia through Increased Bone Resorption without Any Change in Bone Formation. J Musculoskelet Neuronal Interact. 2008 Jul-Sep;8(3):251-6.

Rauner M, Stupphann D, Haas M, et al. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin MRNA ratio. J Rheumatol. 2009 Jan; 36(1):120-6. doi: 10.3899/jrheum.080475.

Hauser B, Zhao S, Visconti MR, et al. Autoantibodies to osteoprotegerin are associated with low hip bone mineral density and History of fractures in axial spondyloarthritis: a cross-sectional observational study. Calcif Tissue Int. 2017 Oct;101(4):375-383. doi: 10.1007/s00223-017-0291-2.

Tan ZY, Bealgey KW, Fang Y, et al. Interleukin-23: Immunological roles and clinical implications. Int J Biochem Cell Biol. 2009 Apr;41(4):733-5. doi: 10.1016/j.biocel.2008.04.027.

Ciccia F, Rizzo A, Triolo G. Subclinical Gut Inflammation in Ankylosing Spondylitis. Curr Opin Rheumatol. 2016 Jan;28(1):89-96. URL: https://iris.unipa.it/bitstream/10447/206724/1/view.pdf.

Li X, Kim K-W, Cho M-L, et al. IL-23 induces receptor activator of NF-ΚB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-ΚB signal pathways. Immunol Lett. 2010 Jan 4;127(2):100-7. doi: 10.1016/j.imlet.2009.10.012

Chisalau B, Cringus L-I, Vreju F, et al. New Insights into IL-17/IL-23 Signaling in Ankylosing Spondylitis (Review). Exp Ther Med. 2020 Oct;20(4):3493-3497. doi: 10.3892/etm.2020.8981.

Van Bezooijen RL, Farih-Sips HCM, Papapoulos SE, Löwik CWGM. Interleukin-17: A New Bone Acting Cytokine In Vitro. J Bone Miner Res. 1999 Sep;14(9):1513-21. doi: 10.1359/jbmr.1999.14.9.1513.

Lambrecht S, Coudenys J, De Keyser F, et al. Reduced Levels of the TGFb Family Member GDF15 in Spondyloarthritis versus Other Rheumatic Diseases. Ann Rheum Dis. 2011;70:A88. doi:10.1136/ard.2010.149021.15

Hinoi E, Ochi H, Takarada T, et al. Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia. J Bone Miner Res. 2012 Apr;27(4):938-49. doi: 10.1002/jbmr.1538.

Lems W, Miceli-Richard C, Haschka J, et al. Bone Involvement in Patients with Spondyloarthropathies. Calcif Tissue Int. 2022 Apr;110(4):393-420. doi: 10.1007/s00223-021-00933-1.

Zhang L, Ouyang H, Xie Z, et al. Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. Exp Mol Med. 2016 Apr 22;48(4):e228. doi: 10.1038/emm.2016.12.

Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006 Nov 27; 203(12):2673-82. doi: 10.1084/jem.20061775.

Poddubnyy D, Sieper J. Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep. 2017 Sep;19(9):55. doi: 10.1007/s11926-017-0681-5.

Sieper J, van der Heijde D. Review: non-radiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013 Mar;65(3):543-51. doi: 10.1002/art.37803.

Neerinckx B, Lories R. Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis. Curr Opin Rheumatol. 2017 Jul;29(4):287292. URL: https://journals.lww.com/co-rheumatology/abstract/2017/07000/mechanisms,_impact_and_prevention_of_pathological.3.aspx.

Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF Therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014 Apr;73(4):710-5. doi: 10.1136/annrheumdis-2012-202698.

Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III measure 1 study. Ann Rheum Dis. 2017 Jun; 76(6):1070-1077. doi: 10.1136/annrheumdis-2016-209730.

Ramiro S, Heijde DVD, Tubergen AV, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014 Aug; 73(8):1455-61. doi: 10.1136/annrheumdis-2014-205178.

Van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008 May; 58(5):1324-31. doi: 10.1002/art.23471.

Van Duivenvoorde LM, Dorris ML, Satumtira N, et al. Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human 2-microglobulin-transgenic rat model of spondylarthritis. Arthritis Rheum. 2012 Oct;64(10):3210-9. doi: doi: 10.1002/art.34600. 2012, 64, 3210–3219.

Llop M, Moreno M, Navarro-Compan V, et al. Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from regisponser-bio. Arthritis Res Ther. 2022 Jan 21;24(1):30. doi: 10.1186/s13075-021-02695-5.

Van der Heijde D, Østergaard M, Reveille JD, et al. Spinal radiographic progression and predictors of progression in patients with radiographic axial spondyloarthritis receiving ixekizumab over 2 years. J Rheumatol. 2022 Mar;49(3):265-273. doi: 10.3899/jrheum.210471.

Lata M, Hettinghouse AS, Liu C. Targeting tumor necrosis factor receptors in ankylosing spondylitis. Ann N Y Acad Sci. 2019 Apr; 1442(1):5-16. doi: 10.1111/nyas.13933. Epub 2018 Jul 15.

Haroon N, Inman RD, Learch TJ, et al. The impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013 Oct;65(10):2645-54. doi: 10.1002/art.38070.

Koo BS, Oh JS, Park SY, et al. Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. Ann Rheum Dis. 2020 Oct;79(10):1327-1332. doi:10.1136/annrheumdis-2019-216741.

Osta B, Lavocat F, Eljaafari A, Miossec P. Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front Immunol. 2014 Sep;2:5:425. doi: 10.3389/fimmu.2014.00425.

Tok MN, Duivenvoorde LM, Kramer I, et al. Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis. Arthritis Rheumatol. 2019 Apr;71(4):612-625. doi: 10.1002/art.40770.

Mease PJ, Landewe R, Rahman P, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the future 5 study. RMD Open. 2021 Jul;7(2):e001600. doi: 10.1136/rmdopen-2021-001600.

Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 Feb; 71(2):258-270. doi: 10.1002/art.40728.

Baeten D, Østergaard M, Wei JCC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295-1302. doi: 10.1136/annrheumdis-2018-213328.

McGonagle D, Watad A, Sharif K, Bridgewood C. Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis. Front Immunol. 2021 Mar; 19:12:614255. doi: 10.3389/fimmu.2021.614255.

Насонов ЕЛ. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4): 397-420. [Nasonov EL. The modern concept of auto-immunity in rheumatology. Nauchno-prakticheskaya revmatologiya. 2023;61(4):397-420. (In Russ.)].

Hasegawa J, Nagashima M, Yamamoto M, et al. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol. 2003 Mar;30(3):474-9.

Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res. 1995 Nov;10(11):1719-25. doi: 10.1002/jbmr.5650101115.

Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007 Jul;19(4):340-5. URL: https://europepmc.org/article/med/17551363.

Toussirot E, Wendling D. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opin Pharmacother. 2005 Jan;6(1):35-43. doi: 10.1517/14656566.6.1.35.

Crotti С , Taranto RD, Orsini F, et al. Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study. Front Med. 2023 Nov;20:10:1282169. doi: 10.3389/fmed.2023.1282169.

Wang L, Guo TZ, Hou S, et al. Bisphosphonates inhibit pain, bone loss, and inflammation in a rat tibia fracture model of complex regional pain syndrome. Anesth Analg. 2016 Oct;123(4):1033-45. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028129/.

Talaat RM, Sidek A, Mosalem A, Kholief A. Effect of bisphosphonates treatment on cytokine imbalance between TH17 and treg in osteoporosis. Inflammopharmacology. 2015 Jun; 23(2-3):119-25. doi: 10.1007/s10787-015-0233-4.

Jarrett SJ, Conaghan PG, Sloan VS, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 2006 May;54(5):1410-4. doi: 10.1002/art.21824.

Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007 Jul;19(4):340-5. URL: https://journals.lww.com/co-rheumatology/abstract/2007/07000/antiinflammatory_treatment_with_bisphosphonates_in.4.aspx.

Maksymowych WP, Lambert R, Jhangri GS, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol. 2001 Jan;28(1):144-55.

Viapiana O, Gatti D, Idolazzi L, et al. Bisphosphonates vs infliximab in ankylosing spondylitis treatment. Rheumatology (Oxford). 2014 Jan;53(1):90-4. doi: 10.1093/rheumatology/ket321.

Li G, Lv GA, Tian L, et al. A retrospective study of alendronate for the treatment of ankylosing spondylitis. Medicine (Baltimore). 2018 May;97(20):e10738. URL: https://pubmed.ncbi.nlm.nih.gov/29768347/.

Russell RG, Graham R. Bisphosphonates: the first 40 years. Bone. 2011 Jul;49(1):2-19. doi: 10.1016/j.bone.2011.04.022.

Cremers S, Drake MT, Ebetino FH, et al. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867.

Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Feb;68(2):175-82. doi: 10.1136/ard.2007.084426.

Arends S, Spoorenberg A, Brouwer E, van der Veer E. Clinical studies on bone-related outcome and the effect of TNF-alpha blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol. 2014 May;26(3):259-68. URL: https://www.researchgate.net/publication/260807899_Clinical_studies_on_bone-related_outcome_and_the_effect_of_TNF-a_blocking_therapy_in_ankylosing_spondylitis.

Haroon NN, Sriganthan J, Al Ghanim N, et al. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systemic review and meta-analysis. Semin Arthritis Rheum. 2014 Oct;44(2):155-61. doi: 10.1016/j.semarthrit.2014.05.008.

Arends S, Wink F, Veneberg J, et al.Bone mineral density improves during 2 years of treatmentwith bisphosphonates in patients with ankylosing spondylitis. Br J Clin Pharmacol. 2021 Feb;87(2):644-651. doi: 10.1111/bcp.14431. Epub 2020 Jul 5.

Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. 2002 Mar;46(3): 766-73. doi: 10.1002/art.10139.

Mok CC, Li OC, Chan KL, et al. Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Scand J Rheumatol. 2015;44:480-6. doi: 10.3109/03009742.2015.1038300

The authors declare that there are no conflicts of interest present.